Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rituxan For Lupus Misses Primary, Secondary Endpoints

This article was originally published in The Pink Sheet Daily

Executive Summary

Widely anticipated EXPLORER data prove disappointing in the wake of PPMS failure.
Advertisement

Related Content

Market Snapshot: After Benlysta Breakthrough, How High The Sky In Lupus?
Genentech Takes Over GlycArt Anti-CD20 Antibody Work
Roche Pushes Respiratory Agenda In Early Inflammatory Pipeline
HGS’ Lupus Candidate Demonstrates Efficacy In Three-Year Continuation Study
HGS: LymphoStat-B For Lupus Not Like Failed Rituxan
HGS First Quarter Results Fair; Bigger News Ahead
Genentech’s Rituxan Fails Against PPMS
Genentech’s Rituxan Fails Against PPMS
HGS Follows Its Single-Cytokine BLISS In Lupus
La Jolla Pharmaceutical Tries Higher-Dose Riquent Against Lupus

Topics

Advertisement
UsernamePublicRestriction

Register

PS067675

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel